Emcure Pharmaceuticals Limited announced today, February 4, 2026, that its Board of Directors has approved the re-appointment of three Non-Executive and Independent Directors for their second consecutive terms. This decision was made based on the recommendation of the Nomination and Remuneration Committee. Dr. Shailesh Kripalu Ayyangar will serve a second term of five years, effective June 2, 2026. Mr. Vijay Keshav Gokhale and Dr. Vidya Rajiv Yeravdekar will each serve their second terms effective April 16, 2026. Mr. Gokhale's term will be for five years, while Dr. Yeravdekar's term will be for three years. All re-appointments are subject to shareholder approval. The company confirmed that these directors are not debarred from holding directorships by any SEBI order and are not related to any other Directors or Key Managerial Personnel of Emcure Pharmaceuticals. Brief profiles highlight Dr. Ayyangar's extensive experience in healthcare and pharmaceuticals, Mr. Gokhale's distinguished career in the Indian Foreign Service and diplomacy, and Dr. Yeravdekar's significant contributions to education and internationalization in higher education.
